Get the Stockscreener App
22.75
0.00%
0.00
After Hours:
22.50
-0.25
-1.10%
Cidara Therapeutics Inc Stock (CDTX) Latest News
Cidara Therapeutics to Participate in World Health - GlobeNewswire
Cidara Therapeutics to present on CD388 at ICAR 2025 - Yahoo Finance
Cidara's Breakthrough H5N1 Flu Drug Takes Center Stage at WHO Emergency Preparedness Meeting - StockTitan
Short Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Increases By 30.7% - Defense World
Cidara Therapeutics Announces Two Presentations on CD388 in - GlobeNewswire
Major Milestone: Cidara's Novel Flu Prevention Drug Completes Massive 5,000-Patient Trial - StockTitan
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology - GlobeNewswire
Revolutionary Universal Flu Drug Shows Promise Against All Strains, Including Bird Flu - StockTitan
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $39.14 Average Target Price from Analysts - Defense World
(CDTX) Long Term Investment Analysis - Stock Traders Daily
Citizens Jmp Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara therapeutics COO Shane Ward sells shares worth $36,542 By Investing.com - Investing.com Australia
Cidara therapeutics COO Shane Ward sells shares worth $36,542 - Investing.com India
Cidara therapeutics chief scientific officer sells shares worth $38,939 - Investing.com India
Cidara Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Cidara therapeutics chief scientific officer sells shares worth $38,939 By Investing.com - Investing.com UK
HC Wainwright Issues Negative Estimate for CDTX Earnings - Defense World
Citizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform Recommendation - Nasdaq
Cidara stock gains on Citizens' bullish view (CDTX:NASDAQ) - Seeking Alpha
Cidara Therapeutics initiated with an Outperform at Citizens JMP - TipRanks
Cidara stock gains on JMP analyst’s upbeat outlook By Investing.com - Investing.com Canada
FY2029 Earnings Forecast for CDTX Issued By HC Wainwright - Defense World
Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention - TipRanks
HC Wainwright Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock Price - Defense World
Cidara stock price target raised to $35 at H.C. Wainwright By Investing.com - Investing.com Canada
Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright - TipRanks
Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments - TipRanks
Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cidara Therapeutics Faces Financial Risks Amid Delayed Annual Report Filing - TipRanks
Cidara Therapeutics Advances with Strong Financial Backing - TipRanks
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Scinai Immunotherapeutics (NASDAQ:SCNI) - Defense World
Cidara Therapeutics: Q4 Earnings Snapshot - Barchart
Cidara Therapeutics reports wider Q4 loss, shares dip - Investing.com
Cidara Therapeutics reports wider Q4 loss, shares dip By Investing.com - Investing.com South Africa
Cidara Therapeutics: Q4 Earnings Snapshot -March 06, 2025 at 05:03 pm EST - Marketscreener.com
Cidara Therapeutics Completes Enrollment in Phase 2b NAVIGATE Trial and Secures $105 Million in Financing - Nasdaq
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Can Cidara's $196M War Chest and 5,000-Patient Trial Transform Flu Prevention? - StockTitan
Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World
(CDTX) Trading Signals - Stock Traders Daily
Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Infectious disease index recovers from -25% low, ends 2024 down 6.28% - BioWorld Online
Cidara Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective February 24, 2025 - Marketscreener.com
Cidara Therapeutics Announces CFO Transition - TipRanks
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short Interest - MarketBeat
Bourla becomes chair of PhRMA - BioCentury
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Invasive Candidiasis Market to Reach New Heights in Growth - openPR
Brokerages Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) Price Target at $32.20 - Defense World
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer - The Manila Times
Cidara CFO steps down, new appointment announced By Investing.com - Investing.com South Africa
Cidara Therapeutics Announces Appointment Of Frank Karbe As Chief Financial Officer - Marketscreener.com
Cidara Therapeutics appoints new CFO amid flu drug trials By Investing.com - Investing.com South Africa
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):